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Abstract
Background: Most cancers maintain telomeres by activating telomerase but a significant minority, mainly of 
mesenchymal origin, utilize an alternative lengthening of telomeres (ALT) mechanism.
Methods: In this study we comparatively analyzed the prognostic relevance of ALT in a monoinstitutional series of 85 
liposarcoma patients as a function of the marker (ALT-associated promyelocytic leukemia bodies (APB) versus 
heterogeneous telomeres) used to classify the tumor.
Results: Independently of the detection approach, ALT proved to be a prognostic discriminant of increased mortality, 
although the prognostic relevance of the two markers appeared at different follow-up intervals (at 10 years for APB and 
15 years for telomeres).
Conclusions: Overall, we confirmed ALT as an indicator of poor clinical outcome in this disease and provide the first 
evidence that the sensitivity of the ALT predictive power depends, at least in part, on the method used.
Background
A hallmark of cancer cells is their limitless proliferative
potential, which is sustained by the activation of a telom-
ere maintenance mechanism (TMM) [1]. In a high per-
centage of human tumors (> 85%), proliferation-
dependent telomere shortening is counterbalanced by the
synthesis of telomeric DNA, which is catalyzed by telom-
erase [2]. However, in few cancers that lack telomerase,
an alternative lengthening of telomeres (ALT) mecha-
nism is used [3]. There may be more than one ALT mech-
anism, but in at least some ALT-positive human cancer
cells telomere length is maintained by recombination-
mediated replication of telomeric DNA [4].
Characteristics of ALT-positive tumor cells include an
extreme heterogeneity of telomere length, with telomeres
ranging from very short to extremely long within the
same cell, as well as the presence of subnuclear structures
termed ALT-associated promyelocytic leukemia (PML)
bodies (APB), which contain telomeric DNA, telomere
binding proteins and proteins involved in DNA recombi-
nation and replication [5]. Assays to detect telomere
length and APB have been developed and alternatively
used to screen human tumor specimens for the occur-
rence of ALT. Available results indicate that ALT is more
common in tumors of mesenchymal and neuroepithelial
origin, including osteosarcomas [6], soft tissue sarcomas
[7] and glioblastoma multiforme [8], and that the pres-
ence of ALT has prognostic significance that depends on
tumor type. Specifically, in liposarcoma ALT proved to be
a strong prognostic discriminant of increased mortality
[9], whereas in glioblastoma the presence of ALT was
associated to a better patient survival [8], suggesting that
the prognostic relevance of ALT presumably reflects the
distinct set of genetic changes that are associated to the
activation of ALT in a given tumor type.
In the present study, we comparatively analyzed the
prognostic relevance of ALT in a monoinstitutional series
of liposarcoma patients as a function of the characteristic
(heterogenoeus telomeres versus APB presence) used to
classify the tumor, with the final aim to identify the most
suitable marker.
Methods
Study population
Samples from 85 liposarcomas, all from adult patients (36
women and 49 men; median age, 52 years; range, 18-91)
treated with a curative intent at the Istituto Nazionale
Tumori of Milan from December 1986 to November 2003
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were available for TMM analysis (Additional file 1, Table
S1). The specimens, which represent a subset of a larger
case series already characterized for TMM (Costa et al,
2006), were consecutive with respect to the availability of
frozen tissue and adequate clinicopathologic and follow-
up information. Twenty-two patients presented with pri-
mary tumors and 63 with recurrent disease (59 local-
regional recurrences and 4 metastases), and they under-
went different surgical procedures according to disease
presentation. The median follow-up for the entire group,
as of December 2008, was 118 months. During the fol-
low-up, 36 patients died for cancer-related causes (30
within 10 years, another 2 from 10 to 15 years, and 4 after
15 years). Postoperative treatment was given when there
was a high risk of recurrence: 18 patients were submitted
to radiotherapy, 8 to chemotherapy, and 5 to radio-che-
motherapy according to the treatment protocols of the
multidisciplinary Soft Tissue Sarcoma Group of the Insti-
tute.
This study was approved by the Institutional Review
Board of the Institute, and all patients provided written
informed consent to donate to the Institute the leftover
tissue after diagnostic procedures.
Detection of APB, telomere length and telomerase activity 
(TA)
Tumor tissue was sampled by a pathologist at the time of
surgery and flash frozen. A fragment of about 100 mg was
cut from each lesion and further subdivided for APB
detection, DNA extraction (for telomere length assess-
ment) and protein extraction (for TA assay). APB were
assayed by combined PML immunofluorescence and
telomere fluorescence in situ hybridization [10]. PML was
detected with anti-PML mouse antibody (Dako Cytoma-
tion; Glostrup, Denmark) plus anti-mouse FITC-labeled
goat antibody (Sigma; St. Louis, MO). Telomere fluores-
cence in situ hybrization (FISH) was performed by dena-
turing slides together with 5'labeled Cy3-(5'CCCTAA3')3
PNA probe (Applied Biosystems, Framingham, MA) for 3
min at 80°C and hybridizing for 3 hs at room tempera-
ture. Slides were washed and counterstained with 4'6-
Diamino-2-phenylindole (DAPI). Images were captured
on a Nikon Eclipse E600 fluorescence microscope using
ACT-1 (Nikon, Tokyo, Japan) image analysis software and
processed using Adobe Photoshop Image Reader 7.0 soft-
ware. APB status was determined according to previously
defined criteria: the presence of an APB was defined by
the localization of a telomeric DNA focus within a
nuclear PML body, sections were scored as APB+ if they
contained APB in ≥0.5% of tumor cells and a tumor was
considered ALT+ when at least one section was APB+. A
set of criteria was used to determine the APB status of
tumor section. An APB was considered to be present only
when the telomeric DNA fluorescence within a PML
body was more intense than that of telomeres, and a cell
was not considered to contain APB if more than 25% of
the co-localized foci occurred outside the nucleus. To
avoid false negatives, at least 2,000 tumor nuclei were
examined, and the assay was repeated in the presence of
negative results.
Telomere length was assessed by pulsed-field gel elec-
trophoresis as previously described [11]. ALT status was
determined by calculating whether the mean, variance,
and semi-interquartile range of the terminal restriction
fragment (TRF) length distribution were greater than 16
kb, 1,000 kb2, and 4 kb, respectively. Tumors were classi-
fied as ALT+ when two of three or three of three of these
criteria were met for unimodal or bimodal TRF length
distributions, respectively. Statistical analysis of TRF
length distributions was done with Telometric software
[12].
TA was measured by the telomeric repeat amplification
protocol (TRAP)[13], with the TRAPeze kit (Intergen,
Oxford, UK) as outlined in Costa et al.[9].
Data analysis
The agreement between APB and TRF data was assessed
by kappa statistics. The clinical end point of the study was
cancer-related survival, and the time of its occurrence
was computed from the date of first diagnosis to the time
of death, or censored at the date of the last recorded fol-
low-up for living patients. Survival curves were estimated
by means of the Kaplan-Meier product limit method [14],
and the Cox proportional hazards model [15] was used to
calculate the hazard ratios (HR) and their confidence
interval (CI). SAS software (SAS Institutes, Inc., Cary,
NC) was used to perform statistical calculations, and a
two-sided P value ≤0.05 was considered statistically sig-
nificant.
Results and discussion
ALT status was determined on each liposarcoma speci-
men by using both APB detection and telomere length
analysis (Fig. 1). Overall, 27 (31.8%) lesions were defined
as ALT+ based on the presence of APB, whereas 24
(27.5%) samples were classified as ALT+ on the basis of
TRF length distribution. A concordance between APB
and TRF results in defining a specimen as ALT+ or ALT-
was found in 66 of 85 cases (77.6%; kappa = 0.469; 95%
CI, 0.265-0.672; P  < 0.0001). Specifically, 16 lesions
(18.8%) were defined as ALT+ and 50 (58.8%) were scored
as ALT- with both detection methods. As regards the
remaining lesions, 11 were defined as ALT+ on the basis
of APB expression but did not show a TRF length distri-
bution consistent with an ALT phenotype, and 8 were
classified as ALT+ on the basis of TRF analysis but
showed a very low percentage of APB-expressing tumor
cells (from 0.01 to 0.2%).Venturini et al. BMC Cancer 2010, 10:254
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The incomplete overlapping of the results obtained
with the two methods is not surprising. In fact, while the
APB assay allows the analysis of individual tumor cells,
the TRF pattern could be misleading due to the admix-
ture of normal and tumor cells present in the specimen.
However, it has been recently shown by Jeyapalan et al.
[16] that some telomerase-negative liposarcomas without
APB express recombination-like activity at the telomere,
suggesting that the incidence of ALT, as defined solely on
the basis of APB expression, could be underestimated.
Thirty of 85 (35.3%) liposarcoma specimens were clas-
sified as TA+ based on positive TRAP results. Among
these, 6 and 8 lesions were defined as ALT+/TA+ based
on the expression of APB or on TRF length distribution,
respectively, thus confirming the possibility that the two
TMM coexist in the same lesion as previously reported
also for other tumor types [3,17,18].
The prognostic significance of TMM was analyzed on
the overall series of 85 patients. TA alone did not prove to
be associated with disease-specific mortality (120
months: TA+ versus TA-, 62.0% versus 60.0%; HR, 0.91;
95% CI, 0.43-1.95; P = 0.814) (180 months: 62.0% versus
48.5%; HR, 0.80; 95% CI, 0.38-1.70; P = 0.566), whereas
significant results were obtained for ALT. Specifically,
when a tumor was defined as ALT+ according to at least
one method (APB or TRF), ALT proved to be prognostic
for 10-year disease-specific survival (ALT+ versus ALT-,
45.5% versus 71.1%; HR, 2.38; 95% CI, 1.15-4.90; P  =
0.019), and such a prognostic value was maintained and
strengthened at 15 years of follow-up (ALT+ versus ALT-,
25.3% versus 71.1%; HR, 2.76; 95% CI, 1.36-5.06; P  =
0.005). These results held true also when APB expression
was used as the only parameter to classify tumors for
ALT. Specifically, the APB presence proved to be an indi-
cator of increased mortality at both 10 years (HR, 2.14;
95% CI, 1.04-4.41; P = 0.040) and 15 years (HR, 2.54; 95%
CI, 1.27-5.11; P  = 0.009) of follow-up (Fig. 2A). Con-
versely, at 10 years of follow-up, patients with a tumor
defined as ALT-positive on the basis of TRF length distri-
bution showed a lower although not statistically signifi-
cant probability of being alive (HR, 1.77; 95% CI, 0.84-
3.73; P = 0.130). Such a trend reached statistical signifi-
cance at 15 years (HR, 2.14; 95% CI, 1.06-4.34; P = 0.035)
(Fig. 2B). These results held true even after adjustment
for TA. In fact, the prognostic significance of APB expres-
sion was evident both at 10 (HR, 2.16; 95% CI, 1.03-4.51;
P = 0.041) and at 15 years (HR, 2.53; 95% CI, 1.24-5.15; P
= 0.011) of follow up, whereas TRF length distribution
provided significant information only at 15 years of fol-
low-up (HR, 2.11; 95% CI, 1.04-4.23; P = 0.038).
Conclusions
In agreement with previously published results based on
APB detection [9], we confirmed ALT as a prognostic dis-
criminant of increased mortality in liposarcomas and
provide the first evidence that sensitivity of the ALT pre-
dictive power depends, at least in part, on the marker
(APB expression versus TRF length distribution) used.
Notwithstanding the good agreement observed between
the two assays in defining the ALT phenotype, they do
not precisely identify the same subset of patients, con-
versely to that observed in glioblastoma multiforme,
where a complete agreement in the results of the two
assays was observed [10]. The incomplete overlapping of
the TRF and APB results may be due to the different
liposarcoma histological subtypes and this heterogeneity
may result in a slight difference on the time-dependence
Figure 1 ALT assays in liposarcomas. A) APB assay: combined PML 
immunofluorescence and telomere fluorescence in situ hybridization 
(FISH) in a frozen section of an ABP-positive liposarcoma. Indirect im-
munofluorescence was used for the PML protein (FITC label, green 
stain). Telomere FISH was done using a Cy3-conjugated telomeric pep-
tide nucleic acid probe (red stain). Nuclei were counterstained with 
4',6-diamidino-2-phenylindole (blue stain). The foci of telomeric DNA 
that co-localize with PML represent APB. B) TRF southern blot analysis. 
Telomere length distribution of a representative series of liposarcomas. 
The lengths of telomeres in ALT-positive cells typically range from < 3 
to > 50 kb. ALT-negative cells typically have a more homogeneous dis-
tribution of telomere length and a shorter average length than ALT-
positive cells.
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of each assay to provide significant prognostic informa-
tion. Overall, APB may be more appropriate than TRF
pattern to assay ALT in tumors because they can be
detected in both frozen and formalin-fixed, paraffin-
embedded tumor samples - as we recently reported in
this tumor type [19] - as well as in needle biopsies or
cytology specimens. However, additional studies aimed at
comparing the prognostic significance of results obtained
with APB and TRF assays in other tumor types are war-
ranted to provide reliable indications on the most appro-
priate ALT-related marker to be used for prognostic
purposes.
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Figure 2 Probability of disease-specific survival as a function of 
ALT, detected by APB presence (A) or TRF length distribution (B), 
according to the criteria reported in Methods, in liposarcoma pa-
tients.
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